Abstract

In in-silico prediction for molecular binding of human genomes, promising results have been demonstrated by deep neural multi-task learning due to its strength in training tasks with imbalanced data and its ability to avoid over-fitting. Although the interrelation between tasks is known to be important for successful multi-task learning, its adverse effect has been underestimated. In this study, we used molecular interaction data of human targets from ChEMBL to train and test various multi-task and single-task networks and examined the effectiveness of multi-task learning for different compositions of targets. Targets were clustered based on sequence similarity in their binding domains and various target sets from clusters were chosen. By comparing the performance of deep neural architectures for each target set, we found that similarity within a target set is highly important for reliable multi-task learning. For a diverse target set or overall human targets, the performance of multi-task learning was lower than single-task learning, but outperformed single-task for the target set containing similar targets. From this insight, we developed Multiple Partial Multi-Task learning, which is suitable for binding prediction for human drug targets.

Highlights

  • Discovering novel compounds that bind to human proteins for use as drugs is gaining increased interest in clinical research

  • The importance of inter-task correlation when performing multi-task learning is known, the adverse effect of multi-task learning for dissimilar tasks has not been adequately investigated

  • We found that multi-task learning can interfere with proper target prediction if the degree of similarity between the targets is low

Read more

Summary

Introduction

Discovering novel compounds that bind to human proteins for use as drugs is gaining increased interest in clinical research. As metabolism within the human body is controlled by the interaction between molecules, predicting and validating potential molecular binding is essential for novel drug development [1]. Only around 10% of candidate drugs are approved after clinical trials because of a lack of effectiveness or unexpected off-target effects [3,4]. In this context, various in-silico-based approaches in pharmaceutical research have been proposed to overcome the low success rate of novel drugs. Predicting molecular binding between the ligand and target enables a highly-efficient virtual screening for specific targets and early avoidance of drug toxicity [6,7]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.